Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) have a 95.83% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) overview
Systemic-onset juvenile idiopathic arthritis (Still’s disease) is a rare and serious form of arthritis that affects children. It causes inflammation not only in the joints, but also in other organs such as the liver, heart, and lungs. It is also known as systemic juvenile rheumatoid arthritis or juvenile-onset Still’s disease. The main symptoms of this condition are high fever, rash, and arthritis. The fever usually occurs daily or twice a day, and the rash is salmon-pink and migrates to different parts of the body. Arthritis may develop later in the course of the disease and affect both large and small joints. Other symptoms may include enlargement of the liver, spleen, or lymph nodes; anemia; and inflammation of the lining of the chest or abdomen. The cause of this condition is unknown, but it may be related to genetic, environmental, and hormonal factors. It is diagnosed by excluding other possible causes of fever and arthritis, and by testing for blood markers of inflammation. Treatment options include glucocorticoids, methotrexate, anakinra, and tocilizumab. These drugs can help reduce inflammation and prevent complications such as growth problems, joint damage, or organ failure.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
